Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache ...

The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition. Calcitonin gene-related peptide (CGRP ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another ...

INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, intensifying the race for India's booming obesity drug market.

Emgality is a prescription injection used for migraine and cluster headaches. Learn about the side effects it can cause and how to manage them.

In recent times, though, Lilly has become less expensive, as the stock slipped 12% from a high reached in March. Is Lilly a buy on the dip? Let's find out. Image source: Getty Images.

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years ...

3. Justifying its valuation with its outlook Eli Lilly's valuation might be a significant stumbling block for some investors. If the stock fails to meet the market's lofty expectations, its shares ...

Emgality is a prescription drug used for migraine headaches. Find out about possible interactions with alcohol, other drugs, supplements, foods, and more.

Lilly's new plant in North Carolina, which is the company's second in the state, uses a mix of automation and robotics to crank out injectable drugs.